Solid Biosciences Inc. (SLDB): Cash & Equivalents
$59.90M
As of 2025-12-31
$159.39M
As of 2026-06-30
-27.2%
3-year compound annual growth
-17.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $59.90M | -25.3% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $80.23M | +8.4% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $74.02M | -52.4% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $155.38M | +30.4% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $119.14M | -23.0% | 2024-03-13, Balance as of period end |
| 2020-12-31 | $154.74M | +103.5% | 2023-03-23, Balance as of period end |
| 2019-12-31 | $76.04M | -12.0% | 2022-03-14, Balance as of period end |
| 2018-12-31 | $86.37M | +65.8% | 2021-03-15, Balance as of period end |
| 2017-12-31 | $52.08M | +578.3% | 2020-03-12, Balance as of period end |
| 2016-12-31 | $7.68M | n/a | 2019-03-13, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $59.90M | -25.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $152.41M | -14.7% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $50.15M | -71.0% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $41.72M | +52.3% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $91.14M | -36.7% |
Compare SLDB, DBVT, TCRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗